Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Tax Provisions (2016 - 2020)

Historic Tax Provisions for Summit Therapeutics (SMMT) over the last 5 years, with Q1 2020 value amounting to $1.3 million.

  • Summit Therapeutics' Tax Provisions rose 2346.4% to $1.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $4.7 million, marking a year-over-year increase of 5177.5%. This contributed to the annual value of -$213000.0 for FY2020, which is 69166.67% down from last year.
  • Latest data reveals that Summit Therapeutics reported Tax Provisions of $1.3 million as of Q1 2020, which was up 2346.4% from $899800.4 recorded in Q4 2019.
  • Summit Therapeutics' 5-year Tax Provisions high stood at $2.0 million for Q4 2017, and its period low was -$644000.0 during Q3 2018.
  • Its 5-year average for Tax Provisions is $1.1 million, with a median of $1.3 million in 2020.
  • In the last 5 years, Summit Therapeutics' Tax Provisions plummeted by 13803.9% in 2018 and then surged by 45928.57% in 2019.
  • Over the past 5 years, Summit Therapeutics' Tax Provisions (Quarter) stood at $1.2 million in 2016, then tumbled by 100.0% to -$38.52 in 2017, then soared by 4229516.58% to $1.6 million in 2018, then tumbled by 44.76% to $899800.4 in 2019, then skyrocketed by 48.44% to $1.3 million in 2020.
  • Its Tax Provisions stands at $1.3 million for Q1 2020, versus $899800.4 for Q4 2019 and $1.3 million for Q3 2019.